Semaglutide API prices are falling sharply as global demand for weight-loss drugs like Ozempic and Wegovy drives rapid manufacturing expansion. With patents set to expire in key markets and Indian companies rolling out lower-priced generics, analysts expect additional price softening. The shift could widen access to these GLP-1 therapies for patients in the months ahead.
Mounjaro sales are sliding across India as Novo Nordisk drives a price war for Ozempic and Wegovy and cheaper semaglutide generics gain traction. Eli Lilly says it’s seeing increased competition but remains confident in Mounjaro’s differentiated benefits for users. The shift highlights how rapidly GLP-1 therapy markets are being reshaped by pricing pressure.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
India’s appetite for weight-loss injectables like Ozempic and Mounjaro is rising fast, with consumers seeking gradual weight reduction. But healthcare professionals are warning that the current regulatory and marketing environment is not keeping pace, increasing the risk of misuse and improper promotion. Calls are growing for stronger oversight to protect patients.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
